This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Conry, J. M. Search for Related Content Social Bookmarking                   What's this?

Significant Drug Interactions in the HIV Patient

Department of Pharmacy Practice, Nesbitt School of Pharmacy, Wilkes University, P.O. Box 111, Stark Learning Center 336, Wilkes-Barre, PA 18766

Current treatment guidelines advocate the use of triple combination antiretroviral therapy for the management of human immunodeficiency virus (HIV) infection with one protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside reverse transcriptase inhibitors (NRTIs). Additionally, patients often receive medications for prophylaxis and treatment of opportunistic infections and comorbid illnesses. Polypharmacy with potent medications places the patient with HIV at significant risk of drug interactions. The purpose of this review is to assist clinicians regarding awareness and management of clinically significant drug interactions frequently encountered in the HIV population.

Pharmacodynamic and pharmacokinetic interactions are discussed in depth with several tables of significant interactions encountered in the patient with HIV. Certain combinations of NRTIs have antagonistic antiretroviral action (e.g., zidovudine plus stavudine), and thus should be avoided. All of the currently available PIs and delavirdine are cytochrome (CYP) 450 inhibitors and can cause significant inhibition of concomitant drug metabolism. Nevirapine is a CYP 450 inducer and can cause induction of drug metabolism, whereas efavirenz may cause inhibition or induction. Drug-herbal interactions are reviewed, including the decreased concentrations of indinavir following the administration of St. John’s wort. Additionally, the pharmacist’s role as an integral member of the HIV patient care team is discussed.

Key Words: HIV • antiretroviral • drug • interaction

Journal of Pharmacy Practice, Vol. 13, No. 6, 499-514 (2000)
DOI: 10.1106/HR55-82T3-D2PJ-9K2W


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?